Hypo-fractionated radiation versus standard radiation for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can understand the study, or your legal representative can
- You have stage IIIA or IIIB non-small cell lung cancer that can be measured on scans
- Your body’s strength is fairly good (ECOG performance status 0 to 2)
- Your scans show no spread to distant sites (PET/CT no metastases, plus brain scan shows none)
- You must be able to meet treatment rules, including organ/blood test requirements and staying on study plan
- You must not have had prior radiation to the chest (thoracic radiotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
This trial studies a different way to deliver radiation to people with locally advanced, non-operable non-small cell lung cancer. It may help by aiming to treat the tumor effectively with a different radiation timing and dose pattern.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This study tests using a shorter course of radiation (hypofractionated radiotherapy) combined with immunotherapy for people with limited-stage small-cell lung cancer. The goal is to see if this approach works better at controlling the cancer and may cause fewer side effects.
This trial tests whether two different schedules (timing) of radiation have different side effects in people with early-stage non-small cell lung cancer. It may help reduce or better understand treatment toxicity while still treating the cancer.
Hear when a new Non Small Cell Lung Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.